DermTech names Australian skin cancer authority to its Melanoma Advisory Board

Jul 01, 2008, 4:00am

La Jolla, Calif. - DermTech, a biotech company that develops molecular diagnostics for the early detection of melanoma and other diseases, has named skin cancer expert Scott Menzies, M.B., B.S., Ph.D., to its Melanoma Advisory Board, PRNewswire reports.

La Jolla, Calif. - DermTech, a biotech company that develops molecular diagnostics for the early detection of melanoma and other diseases, has named skin cancer expert Scott Menzies, M.B., B.S., Ph.D., to its Melanoma Advisory Board, PRNewswire reports.

Dr. Menzies is director of the Sydney Melanoma Diagnostic Centre and an associate professor of dermatology at the University of Sydney in Australia. He has a strong research background in the development of diagnostic technologies for primary melanoma, and is or has been a member of 10 skin cancer advisory committees, including the team that developed the Australian Guidelines for the Management of Cutaneous Melanoma.

PRNewswire quotes George Schwartz, CEO of DermTech, as saying, “Dr. Menzies is an internationally recognized expert, and we are delighted that he will be advising DermTech as we initiate clinical trials for our noninvasive melanoma assay and prepare to enter the Australian marketplace, (where there is) the highest incidence of melanoma in the world.”

Dr. Menzies has authored or co-authored three books, 16 book chapters and 53 journal articles, most related to the detection and treatment of melanoma.